middle.news
Anatara Lifesciences Plans Phase 1 Study Despite Ambiguous Anti-Obesity Data
7:04pm on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
Anatara Lifesciences Plans Phase 1 Study Despite Ambiguous Anti-Obesity Data
7:04pm on Wednesday 29th of April, 2026 AEST
Key Points
Anti-Obesity compound AOC shows significant weight control effects despite inconclusive GLP-1 mechanism data
Phase 1 pharmacokinetic study design underway but potential delay considered
Cash at $0.707 million after $0.327 million operating outflow in Q3 FY26
GaRP gastrointestinal health project advances towards publication with commercial interest
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anatara Lifesciences (ASX:ANR)
OPEN ARTICLE